Igor M Belyakov

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Enhancement of CD8+ T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 177:6336-43. 2006
  2. pmc Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa
    Igor M Belyakov
    Vaccine Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 107:3258-64. 2006
  3. ncbi request reprint Mucosal AIDS vaccines: current status and future directions
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research, Section, Vaccine Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA
    Expert Rev Vaccines 3:S65-73. 2004
  4. pmc Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1578, USA
    J Clin Invest 113:998-1007. 2004
  5. ncbi request reprint Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines
    Igor M Belyakov
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Immunity 20:247-53. 2004
  6. pmc Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:9458-63. 2003
  7. ncbi request reprint A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 178:7211-21. 2007
  8. pmc Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques
    Yongjun Sui
    Vaccine Branch, Biostatistics and Data Management Section, and Laboratory of Experimental Immunology, National Cancer Institute, and Laboratory of Host Defenses and Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:9843-8. 2010
  9. ncbi request reprint Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques
    Yvette Edghill-Smith
    Laboratory of Receptor Biology and Gene Expression, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892 5055, USA
    J Infect Dis 188:1181-91. 2003
  10. ncbi request reprint Avidity of CD8 T cells sharpens immunodominance
    Amiran H Dzutsev
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1578, USA
    Int Immunol 19:497-507. 2007

Collaborators

Detail Information

Publications39

  1. ncbi request reprint Enhancement of CD8+ T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 177:6336-43. 2006
    ..This study demonstrates for the first time a protective adjuvant effect of CpG ODN for a live viral vector vaccine that may overcome CD4 deficiency in the induction of protective CD8(+) T cell-mediated immunity...
  2. pmc Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa
    Igor M Belyakov
    Vaccine Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 107:3258-64. 2006
    ....
  3. ncbi request reprint Mucosal AIDS vaccines: current status and future directions
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research, Section, Vaccine Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA
    Expert Rev Vaccines 3:S65-73. 2004
    ....
  4. pmc Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1578, USA
    J Clin Invest 113:998-1007. 2004
    ..These results and previous clinical trial results support the observation that TCI is a safe and effective strategy for inducing strong mucosal antibody and CTL responses...
  5. ncbi request reprint Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines
    Igor M Belyakov
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Immunity 20:247-53. 2004
    ..Recent understanding of mucosal HIV transmission and of chemokines and integrins in mucosal trafficking can aid design of new strategies to enhance AIDS vaccine efficacy...
  6. pmc Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:9458-63. 2003
    ..These properties, shared with the existing smallpox vaccine, provide a basis for further evaluation of these replication-deficient vaccinia viruses as safer vaccines against smallpox or against complications from vaccinia virus...
  7. ncbi request reprint A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 178:7211-21. 2007
    ..This preferential localization of high-avidity CTL may explain previous differences in vaccination results and may guide future vaccination strategy...
  8. pmc Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques
    Yongjun Sui
    Vaccine Branch, Biostatistics and Data Management Section, and Laboratory of Experimental Immunology, National Cancer Institute, and Laboratory of Host Defenses and Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:9843-8. 2010
    ..Thus, strategic use of molecular adjuvants can provide better mucosal protection through induction of both innate and adaptive immunity...
  9. ncbi request reprint Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques
    Yvette Edghill-Smith
    Laboratory of Receptor Biology and Gene Expression, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892 5055, USA
    J Infect Dis 188:1181-91. 2003
    ....
  10. ncbi request reprint Avidity of CD8 T cells sharpens immunodominance
    Amiran H Dzutsev
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1578, USA
    Int Immunol 19:497-507. 2007
    ..Since most self-reactive T cells of high avidity are depleted in the thymus, the selection of immunodominant epitopes based on the expansion of high-avidity T cells in the periphery reduces the potential for autoimmunity...
  11. doi request reprint Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA Midwest Research Institute, Frederick, MD 21702, USA
    Virology 381:106-15. 2008
    ....
  12. pmc Estimation of low frequency antigen-presenting cells with a novel RELISPOT assay
    Amiran K Dzutsev
    Vaccine Branch, CCR, NCI, NIH, Bethesda, MD 20892 1578, USA
    J Immunol Methods 333:71-8. 2008
    ..Using this RELISPOT (Rosette ELISPOT) method we demonstrate the dynamic interplay between CD8 T cells and professional and non-professional APCs following virus challenge...
  13. pmc Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus
    Alexander Bukreyev
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Cancer Institute, Bethesda, MD 20892 8007, USA
    J Virol 79:9515-26. 2005
    ..Thus, a strong Th2 environment during primary pulmonary immunization with live RSV resulted in early inflammation and a largely nonfunctional primary CTL response but had a minimal effect on the secondary response...
  14. ncbi request reprint Role of alpha3 domain of class I MHC molecules in the activation of high- and low-avidity CD8+ CTLs
    Igor M Belyakov
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Int Immunol 19:1413-20. 2007
    ..Thus, low-avidity CTL may not be able to take advantage of the interaction between CD8 and the alpha3 domain of non-presenting class I MHC molecules, perhaps because of a shorter dwell time for the TCR-MHC interaction...
  15. pmc Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA
    Linda S Wyatt
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 372:260-72. 2008
    ..Thus, truncation of Env enhanced genetic stability as well as serum and mucosal antibody responses, suggesting the desirability of a similar modification in MVA-based candidate HIV vaccines...
  16. pmc TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4⁺ memory T cell loss in SIVmac251-challenged rhesus macaques
    Yongjun Sui
    Vaccine Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, United States
    Vaccine 30:59-68. 2011
    ..Overall, these data highlight one unrecognized role of adjuvant in HIV vaccine development, and show that vaccines can produce a surprising discordance between CD4(+) T cell levels and SIV viral load...
  17. pmc Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice
    Qing Zhu
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 120:607-16. 2010
    ..Therefore, selective TLR ligand combinations can increase protective efficacy by increasing the quality rather than the quantity of T cell responses...
  18. pmc Memories that last forever: strategies for optimizing vaccine T-cell memory
    Jeffrey D Ahlers
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA
    Blood 115:1678-89. 2010
    ..In this review we will focus on discussing mechanisms involved in T-cell memory and provide promising new approaches toward expanding current vaccine strategies to enhance antiviral memory...
  19. pmc The IL-15 receptor {alpha} chain cytoplasmic domain is critical for normal IL-15Ralpha function but is not required for trans-presentation
    Zheng Wu
    Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1674, USA
    Blood 112:4411-9. 2008
    ..These experiments collectively indicate that IL-15Ralpha can act in cis in addition to acting in trans to present IL-15 to responding cells...
  20. pmc The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response
    Alexander Kotelkin
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
    J Virol 80:5958-67. 2006
    ..Thus, the NS2 protein of HRSV suppresses the CTL component of the adaptive immune response, and this appears to be a consequence of its suppression of type I IFN...
  21. ncbi request reprint Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines
    Jeffrey D Ahlers
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 USA
    Curr Mol Med 3:285-301. 2003
    ..In this review we will discuss the application and delivery of cytokines, costimulatory molecules, and chemokines toward improving current vaccine strategies...
  22. pmc Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses
    James T Snyder
    Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1578, USA
    J Virol 78:7052-60. 2004
    ..1-positive individuals, representing almost half the population...
  23. doi request reprint Strategies for optimizing targeting and delivery of mucosal HIV vaccines
    Jeffrey D Ahlers
    Division of AIDS, NIAID, NIH, Rockville, MD 20817, USA
    Eur J Immunol 39:2657-69. 2009
    ..Here, we discuss novel vaccine strategies and adjuvants for optimizing mucosal delivery of HIV vaccines...
  24. pmc A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L
    Jeffrey D Ahlers
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 99:13020-5. 2002
    ..These results argue for a push-pull approach to maximize vaccine efficacy, especially for HIV and cancer...
  25. ncbi request reprint New paradigms for generating effective CD8+ T cell responses against HIV-1/AIDS
    Jeffrey D Ahlers
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20817, USA
    Discov Med 9:528-37. 2010
    ..Here, we highlight factors considered essential for effective HIV-1 vaccine CD8+ T cell responses: vaccine antigens, quality, magnitude and breadth, mucosal targeting, and formation of CD8+ T cell mucosal memory...
  26. pmc Progress on new vaccine strategies for the immunotherapy and prevention of cancer
    Jay A Berzofsky
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 113:1515-25. 2004
    ..This review examines the fundamental immunologic advances and the novel vaccine strategies arising from these advances, as well as the early clinical trials studying new approaches to treat or prevent cancer...
  27. pmc Progress on new vaccine strategies against chronic viral infections
    Jay A Berzofsky
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, The Center for Cancer Research, National Cancer Institute NIH, 10 Center Drive, Bethesda, MD 20892, USA
    J Clin Invest 114:450-62. 2004
    ..We also explore novel strategies for increasing the immunogenicity and efficacy of vaccines...
  28. doi request reprint Lack of IL-7 and IL-15 signaling affects interferon-γ production by, more than survival of, small intestinal intraepithelial memory CD8+ T cells
    Dmitry Isakov
    Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Eur J Immunol 41:3513-28. 2011
    ..Taken together, these results reveal that survival factors, as well as the functional activity, of antigen-specific CD8(+) T cells in the SI-IEL compartments may markedly differ from their counterparts in peripheral lymphoid tissues...
  29. pmc Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines
    Qing Zhu
    Vaccine Branch, Center for Cancer Research, and Laboratory of Experimental Immunology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 105:16260-5. 2008
    ....
  30. doi request reprint Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines
    Jeffrey D Ahlers
    Division of AIDS, NIAID, National Institutes of Health, 6700 Rockledge Dr, Bethesda, MD 20817, USA
    Trends Mol Med 15:263-74. 2009
    ..Here, we discuss current vaccine strategies for optimizing the induction of immune responses by the recruitment of DCs and the targeting of vaccine antigens to DCs...
  31. ncbi request reprint DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses
    Arya Biragyn
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 100:1153-9. 2002
    ....
  32. ncbi request reprint Molecular mechanisms and biological significance of CTL avidity
    James T Snyder
    Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Curr HIV Res 1:287-94. 2003
    ....
  33. doi request reprint Molecular pathways regulating CD4(+) T cell differentiation, anergy and memory with implications for vaccines
    Jeffrey D Ahlers
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20817, USA
    Trends Mol Med 16:478-91. 2010
    ..Here, we discuss lineage instructive programs that regulate CD4(+) T cell differentiation and memory and how to translate this knowledge into vaccines and immunotherapies that promote protective immune responses...
  34. doi request reprint Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS
    Jeffrey D Ahlers
    NIAID, NIH, Bethesda, MD 20817, USA
    Trends Immunol 31:120-30. 2010
    ..Here, we discuss qualitative parameters of the CD8(+) CTL response and mechanisms operative in the control of persistent virus infections and suggest new strategies for design and delivery of HIV vaccines...
  35. ncbi request reprint Expression of immunomodulating molecules by recombinant viruses: can the immunogenicity of live virus vaccines be improved?
    Alexander Bukreyev
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8007, USA
    Expert Rev Vaccines 1:233-45. 2002
    ..For this type of vaccine, expression of tumor antigens and one or more immunomodulating molecules by one or several recombinant viruses has been proposed...
  36. ncbi request reprint Cytokines in the thymus: production and biological effects
    Alexandr A Yarilin
    Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Med Chem 11:447-64. 2004
    ..The functions of many cytokines in the thymus are not established up to now. Detailed analysis of the "minor cytokine network" and intrathymic cytokine effects will reveal some unknown events of thymus physiology...
  37. ncbi request reprint Late effects of the Chernobyl radiation accident on T cell-mediated immunity in cleanup workers
    Oleg Kuzmenok
    Laboratory on Thymus Research, Department of Immunology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Av Brasil, 4365 Manguinhos 21045 900 Brazil
    Radiat Res 159:109-16. 2003
    ....
  38. pmc Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection
    Todd M Allen
    Wisconsin Regional Primate Research Center, University of Wisconsin, Madison, WI 53715, USA
    J Virol 76:10507-11. 2002
    ..By themselves, these strong CTL responses failed to control SIVmac239 replication...
  39. pmc Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels
    Ranajit Pal
    Advanced BioScience Laboratories, Inc, Kensington, Maryland 20895, USA
    J Virol 80:3732-42. 2006
    ..Thus, systemic immunization with ALVAC-HIV-1 vaccine candidates elicits anti-HIV-1 immune responses able to contain virus replication also at mucosal sites in macaques...